miR199a-5p inhibits hepatic insulin sensitivity via suppression of ATG14-mediated autophagy

Bo Li1, Xiangsong Wu2, Hanbei Chen1

  • 1Department of Endocrinology, XinHua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.

Cell Death & Disease
|March 16, 2018
PubMed

Insights

MicroRNA 199a-5p (miR199a-5p) regulates hepatic insulin sensitivity by controlling autophagy through ATG14. Upregulated miR199a-5p in diabetes patients correlates with impaired autophagy and insulin resistance.

Area of Science:

  • Metabolic Diseases
  • Molecular Biology
  • Cellular Biology

Background:

  • MicroRNAs (miRNAs) play a role in metabolic diseases like diabetes.
  • Hepatic insulin sensitivity is crucial for glucose homeostasis.

Purpose of the Study:

  • To investigate the role of miR199a-5p in regulating hepatic insulin sensitivity.
  • To elucidate the underlying mechanism involving autophagy and ATG14.

Main Methods:

  • In vivo studies using C57BL/6J WT mice with miR199a-5p inhibition or overexpression.
  • In vitro studies using HepG2 cells and primary hepatocytes.
  • Analysis of autophagy-related proteins (ATG14, LC3, BECLIN1) and insulin signaling pathways.
  • Examination of miR199a-5p expression in liver samples from diabetes patients.

Main Results:

  • miR199a-5p inhibition decreased glucose tolerance, while overexpression improved it.
  • miR199a-5p directly targets ATG14, regulating autophagy.
  • miR199a-5p modulates insulin signaling pathway phosphorylation.
  • Upregulated miR199a-5p and reduced ATG14/autophagy were observed in diabetes patients.

Conclusions:

  • miR199a-5p is a novel regulator of hepatic insulin sensitivity.
  • The mechanism involves miR199a-5p-mediated regulation of ATG14 and autophagy.
  • miR199a-5p represents a potential therapeutic target for diabetes.

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.9K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
302
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K